TY - JOUR
T1 - Practitioner review
T2 - current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents
AU - Cortese, Samuele
AU - Holtmann, Martin
AU - Banaschewski, Tobias
AU - Buitelaar, Jan
AU - Coghill, David
AU - Danckaerts, Marina
AU - Dittmann, Ralf W.
AU - Graham, John
AU - Taylor, Eric
AU - Sergeant, Joseph
AU - European ADHD Guidelines Grp
N1 - © 2013 The Authors. Journal of Child Psychology and Psychiatry © 2013 Association for Child and Adolescent Mental Health.
PY - 2013/3
Y1 - 2013/3
N2 - Background: Medication is an important element of therapeutic strategies for ADHD. While medications for ADHD are generally well-tolerated, there are common, although less severe, as well as rare but severe adverse events AEs during treatment with ADHD drugs. The aim of this review is to provide evidence- and expert-based guidance concerning the management of (AEs) with medications for ADHD. Methods: For ease of use by practitioners and clinicians, the article is organized in a simple question and answer format regarding the prevalence and management of the most common AEs. Answers were based on empirical evidence from studies (preferably meta-analyses or systematic reviews) retrieved in PubMed, Ovid, EMBASE and Web of Knowledge through 30 June 2012. When no empirical evidence was available, expert consensus of the members of the European ADHD Guidelines Group is provided. The evidence-level of the management recommendations was based on the SIGN grading system. Results: The review covers monitoring and management strategies of loss of appetite and growth delay, cardiovascular risks, sleep disturbance, tics, substance misuse/abuse, seizures, suicidal thoughts/behaviours and psychotic symptoms. Conclusion: Most AEs during treatment with drugs for ADHD are manageable and most of the times it is not necessary to stop medication, so that patients with ADHD may continue to benefit from the effectiveness of pharmacological treatment.
AB - Background: Medication is an important element of therapeutic strategies for ADHD. While medications for ADHD are generally well-tolerated, there are common, although less severe, as well as rare but severe adverse events AEs during treatment with ADHD drugs. The aim of this review is to provide evidence- and expert-based guidance concerning the management of (AEs) with medications for ADHD. Methods: For ease of use by practitioners and clinicians, the article is organized in a simple question and answer format regarding the prevalence and management of the most common AEs. Answers were based on empirical evidence from studies (preferably meta-analyses or systematic reviews) retrieved in PubMed, Ovid, EMBASE and Web of Knowledge through 30 June 2012. When no empirical evidence was available, expert consensus of the members of the European ADHD Guidelines Group is provided. The evidence-level of the management recommendations was based on the SIGN grading system. Results: The review covers monitoring and management strategies of loss of appetite and growth delay, cardiovascular risks, sleep disturbance, tics, substance misuse/abuse, seizures, suicidal thoughts/behaviours and psychotic symptoms. Conclusion: Most AEs during treatment with drugs for ADHD are manageable and most of the times it is not necessary to stop medication, so that patients with ADHD may continue to benefit from the effectiveness of pharmacological treatment.
KW - medication
KW - PHARMACOLOGICAL-TREATMENT
KW - adverse events
KW - ADHD
KW - European
KW - ATTENTION-DEFICIT/HYPERACTIVITY DISORDER
KW - TIC DISORDERS
KW - SERIOUS CARDIOVASCULAR EVENTS
KW - OROS METHYLPHENIDATE
KW - OF-THE-LITERATURE
KW - STIMULANT MEDICATIONS
KW - SUBSTANCE USE DISORDERS
KW - DEFICIT-HYPERACTIVITY DISORDER
KW - recommendations
KW - SUICIDE ATTEMPTS
KW - management
U2 - 10.1111/jcpp.12036
DO - 10.1111/jcpp.12036
M3 - Article
C2 - 23294014
SN - 0021-9630
VL - 54
SP - 227
EP - 246
JO - Journal of Child Psychology and Psychiatry
JF - Journal of Child Psychology and Psychiatry
IS - 3
ER -